Tcr2 Therapeutics Stock Fundamentals
Tcr2 Therapeutics fundamentals help investors to digest information that contributes to Tcr2 Therapeutics' financial success or failures. It also enables traders to predict the movement of Tcr2 Stock. The fundamental analysis module provides a way to measure Tcr2 Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tcr2 Therapeutics stock.
Tcr2 |
Tcr2 Therapeutics Company Return On Equity Analysis
Tcr2 Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Tcr2 Therapeutics Return On Equity | -0.91 |
Most of Tcr2 Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Tcr2 Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, Tcr2 Therapeutics has a Return On Equity of -0.9146. This is 96.18% lower than that of the Biotechnology sector and 97.49% lower than that of the Health Care industry. The return on equity for all United States stocks is 195.03% higher than that of the company.
Tcr2 Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Tcr2 Therapeutics's current stock value. Our valuation model uses many indicators to compare Tcr2 Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Tcr2 Therapeutics competition to find correlations between indicators driving Tcr2 Therapeutics's intrinsic value. More Info.Tcr2 Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Tcr2 Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Tcr2 Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tcr2 Therapeutics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tcr2 Therapeutics could also be used in its relative valuation, which is a method of valuing Tcr2 Therapeutics by comparing valuation metrics of similar companies.Tcr2 Therapeutics is currently under evaluation in return on equity category among its peers.
Tcr2 Fundamentals
| Return On Equity | -0.91 | |||
| Return On Asset | -0.35 | |||
| Current Valuation | (73.69 M) | |||
| Shares Outstanding | 39.26 M | |||
| Shares Owned By Insiders | 1.50 % | |||
| Shares Owned By Institutions | 54.31 % | |||
| Number Of Shares Shorted | 360.89 K | |||
| Price To Book | 0.22 X | |||
| EBITDA | (89.62 M) | |||
| Net Income | (151.82 M) | |||
| Cash And Equivalents | 175.99 M | |||
| Cash Per Share | 4.55 X | |||
| Total Debt | 58.23 M | |||
| Debt To Equity | 0.29 % | |||
| Current Ratio | 5.02 X | |||
| Book Value Per Share | 2.58 X | |||
| Cash Flow From Operations | (101.46 M) | |||
| Short Ratio | 1.29 X | |||
| Earnings Per Share | (4.20) X | |||
| Target Price | 6.43 | |||
| Number Of Employees | 58 | |||
| Beta | 1.93 | |||
| Market Capitalization | 58.11 M | |||
| Total Asset | 208.24 M | |||
| Retained Earnings | (501.34 M) | |||
| Working Capital | 113.56 M | |||
| Z Score | -3.54 | |||
| Net Asset | 208.24 M |
Pair Trading with Tcr2 Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tcr2 Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tcr2 Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Dupont De could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Dupont De when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Dupont De - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Dupont De Nemours to buy it.
The correlation of Dupont De is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Dupont De moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Dupont De Nemours moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Dupont De can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Other Consideration for investing in Tcr2 Stock
If you are still planning to invest in Tcr2 Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Tcr2 Therapeutics' history and understand the potential risks before investing.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |